Definitive chemoradiotherapy (CRT) for anal cancer spares patients the morbidity of a colostomy surgery and optimizes cancer outcomes. CRT, however, has introduced a unique acute and chronic toxicity profile, which has greatly improved over the years with the introduction of advanced radiotherapy techniques. This article provides the multidisciplinary care team with practical tools to mitigate and manage acute and chronic complications from definitive treatment of anal cancer.
Search Results
Page:12
Acute and Chronic Complications After Treatment of Locoregional Anal Cancer: Prevention and Management Strategies
Leah Katz, David P. Horowitz, and Lisa A. Kachnic
A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis
Reith R. Sarkar, Katherine E. Fero, Daniel M. Seible, Neil Panjwani, Rayna K. Matsuno, and James D. Murphy
itself (eg, pancreatitis), and radiation toxicity. Hospitalizations for nonlocal/distant disease included those due to thromboembolic events, cytopenia, dehydration, nausea or vomiting, malnutrition and cachexia, ascites, pathologic fracture, and
Evolving Treatment of Soft Tissue Sarcoma
Suzanne George
primary modality and RT is a category 2B recommendation, based on the lack of data for favorable outcomes and the risk of radiation toxicity to normal organs in this anatomic location. Further guidance on the use of RT should come from results of the
Lung Stereotactic Body Radiotherapy for Early-Stage NSCLC in Patients With Prior Pneumonectomy: A Case Report
Daniel R. Simpson, Parag Sanghvi, and Ajay P. Sandhu
required supplemental oxygen after therapy. The second patient did expire after therapy, although the clinical picture of lobar consolidation with leukocytosis and positive sputum cultures suggests that infection was the likely cause rather than radiation
Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma
Amol K. Narang and Stephanie A. Terezakis
, prescription dose, and planning techniques have significantly reduced the radiation exposure of normal tissue, concerns regarding late radiation toxicities have prompted investigators to explore whether omission of RT from the treatment regimen is feasible. As
Locally Advanced Colon Cancer: Evaluation of Current Clinical Practice and Treatment Outcomes at the Population Level
Charlotte E.L. Klaver, Lieke Gietelink, Willem A. Bemelman, Michel W.J.M. Wouters, Theo Wiggers, Rob A.E.M. Tollenaar, Pieter J. Tanis, and on behalf of the Dutch Surgical Colorectal Audit Group
allocation bias, because the most advanced tumors were probably allocated to neoadjuvant therapy. Because of concerns regarding radiation toxicity, mainly to the small bowel, the use of chemoRT for LACC remains controversial. 30 Results of one study in
Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma
Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou
methods and technologies are constantly changing. Moreover, the study lacked details on radiation toxicity. Therefore, prospective studies and improved follow-up strategies are necessary for further study. Conclusions PORT is an important factor in
The Optimal Use of Radiotherapy in Small Cell Lung Cancer
David B. Shultz, John C. Grecula, James Hayman, Maximilian Diehn, and Billy W. Loo Jr
( ClinicalTrials.gov identifier: NCT00433563). Normal Tissue Dose Constraints: The organs at risk for radiation toxicity depend on tumor location and extent. For similar RT prescription doses, the normal tissue constraints used for non-small cell lung cancer
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019
Featured Updates to the NCCN Guidelines
P. Kumar Rao, Christopher Barker, Daniel G. Coit, Richard W. Joseph, Miguel Materin, Ramesh Rengan, Jeffrey Sosman, John A. Thompson, Mark R. Albertini, Genevieve Boland, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossman, Valerie Guild, Douglas Johnson, Giorgos Karakousis, Julie R. Lange, ScM, Kim Margolin, Sameer Nath, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Evan Wuthrick, Nicole R. McMillian, and Anita Engh
-Ardakani A , . Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma . Int J Radiat Oncol Biol Phys 2013 ; 86 : 510 – 515 . 23507292 10.1016/j
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Featured Updates to the NCCN Guidelines
Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, Shaili Aggarwal, and Sara Espinosa
’s high potency as a radiosensitizer, it requires reduced dosing when used concurrently with radiation to avoid radiation toxicity. 35 In a comparative study, the disease control and toxicity profile were found to be similar between cisplatin and
Page:12
